Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive.
Investigator: Thomas Guzzo, MD, MPH – Assistant Professor, University of Pennsylvania Reducing Morbidity from Surgery and Physician Counseling of Treatment Costs Dr. Guzzo has had a very prolific second year as a PCF Young Investigator as evidenced by his publication of ten scientific and clinical reports. His primary research aims.
Investigator: Eleni Efstathiou, MD, PhD – Assistant Professor, University of Texas, M.D. Anderson Cancer Center Biomarker Driven Application of Therapy Androgens (male hormones such as testosterone) fuel prostate cancer growth and survival. Androgens are synthesized in the testis and adrenal glands. Therapeutic agents that block the production of androgens (androgen.
PCF-Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) As part of its aggressive plan to fund and accelerate research—and to speed the results to patients worldwide—PCF has invested more than $45 million in a consortium of 13 leading cancer centers, featuring some of the world’s most respected prostate cancer clinical.
The Prostate Cancer Foundation Human Capital Initiative Recognition Awards PCF and its partners grant awards that recognize top presentations at international cancer research meetings. Recognition Awards go to investigators not currently funded by PCF who have a record of outstanding accomplishments in prostate cancer research. The AACR-PCF Prostate Cancer Research.